- - | |
---|---|
Price | |
- | |
Difference | - (-) |
ISIN | CH1110760852 |
Symbol | PPGN |
Exchange | FINRA other OTC Issues |
Currency | USD |
Sector | Other |
Security type | Stock |
Market cap (m) | 1,046 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 36.5641 USD |
High | 36.5641 USD |
Low | 36.5641 USD |
Close (prev. day) | 36.5641 USD |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | 360 |
Date | Headline | Download | |
2024/09/27 | Global Equity Ratings | ||
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings |
- - | |
---|---|
Price | |
- | |
Difference | - (-) |
ISIN | CH1110760852 |
Symbol | PPGN |
Exchange | FINRA other OTC Issues |
Currency | USD |
Sector | Other |
Security type | Stock |
Market cap (m) | 1,046 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 36.5641 USD |
High | 36.5641 USD |
Low | 36.5641 USD |
Close (prev. day) | 36.5641 USD |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | - | - | - |
Perf (abs.) | - | - | - |
Beta | 1.41 | 1.37 | 1.36 |
Volatility | - | - | - |
Ø price 5 days | Ø volume 5 days (pcs.) | - USD (-) |
Ø price 30 days | Ø volume 30 days (pcs.) | - USD (-) |
Ø price 100 days | Ø volume 100 days (pcs.) | - USD (-) |
Ø price 250 days | Ø volume 250 days (pcs.) | - USD (-) |
YTD High | date | - USD (-) |
YTD Low | date | - USD (-) |
52 Weeks High | date | - USD (-) |
52 Weeks Low | date | - USD (-) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
SIX Swiss Exchange | 2024/10/18 | 17:30 | 29.75 CHF | 0.66 | 293 |
London Stock Exchange | 2024/05/07 | 13:59 | 31.25 CHF | 0.30 | 1 |
FINRA other OTC Issues | - | - | - | 0.00 | 1 |
POLYPEPTIDE GROUP AG |
- - |
Neuhofstrasse 24 - 6340 Baar |
Telefon: +41-43-502-05-80 |
Fax: + |
E-mail: info@polypeptide.com |
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland. |
Juan-José Gonzalez | Chairman of Managing Board |
Christina del Vecchio | Member of Executive Committee |
Jens Fricke | Member of Executive Committee |
Marc Augustin | Member of Executive Committee |
Neil Thompson | Member of Executive Committee |
Stéphane Varray | Member of Executive Committee |
Beat In-Albon | Member of the administrative board |
Jane Salik | Member of the administrative board |
Patrick Aebischer | Member of the administrative board |
Philippe Weber | Member of the administrative board |
Erik Schropp | Member of the administrative board |
Peter Wilden | Chairman of the administrative boar |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer